Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 5, 2011, Pages 691-704

  Alsauskas, Zygimantas C ^a   Medapalli, Raj Kiran ^b   Ross, Michael J ^b  

^a University of Louisville School of Medicine   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; collapsing glomerulopathy; FSGS; HIV associated nephropathy; HIVAN

Indexed keywords

ACICLOVIR; ADEFOVIR; AMPHOTERICIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; ATAZANAVIR; BETA LACTAM ANTIBIOTIC; CIDOFOVIR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSCARNET; FOSINOPRIL; GANCICLOVIR; INDINAVIR; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STEROID; STREPTOMYCIN; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; BONE DISEASE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CRYSTALLURIA; DIABETIC NEPHROPATHY; DOSE KIDNEY FUNCTION RELATION; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; GENETIC SUSCEPTIBILITY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY EPITHELIUM; KIDNEY FAILURE; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE ACIDOSIS; LACTIC ACIDOSIS; MORBIDITY; MORTALITY; NEPHROGENIC DIABETES INSIPIDUS; NEPHROLITHIASIS; NEPHROTOXICITY; NONHUMAN; OSTEOMALACIA; PROTEINURIA; PYURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TUBULAR DYSFUNCTION; UREMIA; UROLITHIASIS;

ADULT; ANTI-HIV AGENTS; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; MIDDLE AGED;

EID: 79952592813     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.535518     Document Type: Review

References (117)

1. UNAIDS. AIDS epidemic update: November 2009. 2009
2. Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002;61:195-202 (Pubitemid 34075147)
3. Gupta SK, Mamlin BW, Johnson CS, et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004;61:1-6 (Pubitemid 38100837)
4. Wyatt CM, Winston JA, Malvestutto CD, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007;21:2101-3 (Pubitemid 47462160)
5. Mulenga LB, Kruse G, Lakhi S, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 2008;22:1821-7
6. Gardner LI, Holmberg SD, Williamson JM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003;32:203-9 (Pubitemid 36222723)
7. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004;39:1199-206 (Pubitemid 40169320)
8. Wyatt CM, Hoover DR, Shi Q, et al. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr 2010;55:73-7
9. DAgati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998;18:406-21 (Pubitemid 28340464)
10. Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:669-73 (Pubitemid 14164641)
11. Palella FJ Jr, Delaney KM, Moorman AC, et al.; HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60 (Pubitemid 28135961)
12. Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol 2002;13:2997-3004 (Pubitemid 35386920)
13. USRDS. USRDS 2009 Annual Data Report. 2009
14. Shahinian V, Rajaraman S, Borucki M, et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000; 35: 884-8 (Pubitemid 30238201)
15. Wyatt CM, Morgello S, Katz-Malamed R, et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 2009;75:428-34
16. Han TM, Naicker S, Ramdial PK, et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006;69:2243-50 (Pubitemid 43882112)
17. Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008;28:478-86 (Pubitemid 351501614)
18. Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS 2000;14:637-45
19. Fine DM, Perazella MA, Lucas GM, et al. Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am J Kidney Dis 2008;51:504-14 (Pubitemid 351273482)
20. Izzedine H, Deray G. The nephrologist in the HAART era. AIDS 2007;21:409-21
21. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004;66:1145-52 (Pubitemid 39121021)
22. Nochy D, Glotz D, Dosquet P, et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 1993;8:11-19 (Pubitemid 23050590)
23. Kopp JB, Winkler C. HIV-associated nephropathy in African Americans. Kidney Int Suppl 2003;83:S43-9 (Pubitemid 36126842)
24. Leventhal JS, Ross MJ. Pathogenesis of HIV-associated nephropathy. Semin Nephrol 2008;28:523-34
25. Freedman BI, Soucie JM, Stone SM, et al. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999;34:254-8 (Pubitemid 29362089)
26. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185-92
27. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008;40:1175-84
28. Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005;130:620-7 (Pubitemid 43899767)
29. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African-Americans. Science 2010;329:841-5
30. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010;128:345-50
31. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-85 (Pubitemid 40720806)
32. Hammer SM, Eron JJJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-70
33. Ifudu O, Rao TK, Tan CC, et al. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 1995;15:217-21
34. Wali RK, Drachenberg CI, Papadimitriou JC, et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy [letter]. Lancet 1998;352:783-4 (Pubitemid 28404562)
35. Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001;344:1979-84 (Pubitemid 32568152)
36. Szczech LA, Edwards LJ, Sanders LL, et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002;57:336-41 (Pubitemid 34477470)
37. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006;21:2809-13 (Pubitemid 44542235)
38. Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence ofHIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004;18:541-46 (Pubitemid 38365883)
39. Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005;16:2412-20 (Pubitemid 41725059)
40. Yahaya I, Uthman AO, Uthman MM. Interventions for HIV-associated nephropathy. Cochrane Database Syst Rev 2009:CD007183
41. Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996;101:41-8 (Pubitemid 26285939)
42. Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000;58:1253-60
43. Laradi A, Mallet A, Beaufils H, et al. HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes Nephrologiques d'Ile de France. J Am Soc Nephrol 1998;9:2327-35
44. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49:12-26 (Pubitemid 44918179)
45. Jones DW, Hall JE. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure and evidence from new hypertension trials. Hypertension 2004;43:1-3 (Pubitemid 38031902)
46. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-290
47. Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996;28:202-8 (Pubitemid 26286655)
48. Burns GC, Paul SK, Toth IR, et al. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997;8:1140-46 (Pubitemid 27427222)
49. Wei A, Burns GC, Williams BA, et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003;64:1462-71 (Pubitemid 37153814)
50. Szczech LA, Winston JA. The impact of antiretroviral therapy on HIVAN. Kidney Int 2004;65:1114; author reply 1115
51. Ingulli E, Tejani A, Fikrig S, et al. Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 1991;119:710-16
52. Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008;46:1271-81 (Pubitemid 351589914)
53. Peters PJ, Moore DM, Mermin J, et al. Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 2008;74:845-7
54. Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008;22:481-7 (Pubitemid 351317289)
55. Longenecker CT, Scherzer R, Bacchetti P, et al. HIV viremia and changes in kidney function. AIDS 2009;23:1089-96
56. Mocroft A, Wyatt C, Szczech L, et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 2009;23:71-82
57. Rachakonda AK, Kimmel PL. CKD in HIV-infected patients other than HIV-associated nephropathy. Adv Chronic Kidney Dis 2010;17:83-93
58. Gorriz JL, Rovira E, Sancho A, et al. IgA nephropathy associated with human immuno deficiency virus infection: antiproteinuric effect of captopril. Nephrol Dial Transplant 1997;12:2796-7 (Pubitemid 27520730)
59. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009; 1-161. Available from http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 21 October 2010]
60. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50:3297-304 (Pubitemid 44527501)
61. Ortiz A, Justo P, Sanz A, et al. Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir Ther 2005;10:185-90 (Pubitemid 40767645)
62. Bendele RA, Richardson FC. Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum Pathol 2002;33:574 (Pubitemid 34747881)
63. Gitman MD, Hirschwerk D, Baskin CH, et al. Tenofovir-induced kidney injury. Expert Opin Drug Saf2007;6:155-64 (Pubitemid 46380809)
64. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273-81 (Pubitemid 46883481)
65. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-78
66. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8 (Pubitemid 40490248)
67. Young B, Buchacz K, Baker RK, et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:178-87
68. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007;12:1165-73
69. Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006;7:105-11
70. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-8 (Pubitemid 351263473)
71. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009;23:1971-5
72. Parsonage MJ, Wilkins EG, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005;6:341-6 (Pubitemid 41335143)
73. Gagnon RF, Tecimer SN, Watters AK, et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000;36:507-15
74. Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis 2010;17:72-82
75. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25 (Pubitemid 27337395)
76. Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002;162:1493-501 (Pubitemid 34747483)
77. Kopp JB, Falloon J, Filie A, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002;34:1122-8 (Pubitemid 34289686)
78. Chan-Tack KM, Truffa MM, Struble KA, et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007;21:1215-18 (Pubitemid 46763296)
79. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004;44:e81-4 (Pubitemid 39445931)
80. Izzedine H, M'rad MB, Bardier A, et al. Atazanavir crystal nephropathy. AIDS 2007;21:2357-58
81. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med 2006;52:296-7 (Pubitemid 44862772)
82. Krishnan M, Nair R, Haas M, et al. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis 2000;36:1075-8
83. Crowther MA, Callaghan W, Hodsman AB, et al. Dideoxyinosine-associated nephrotoxicity. AIDS 1993;7:131-2
84. Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 2005;19:844-5 (Pubitemid 40834761)
85. Nelson M, Azwa A, Sokwala A, et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 2008;22:1374-6
86. Morris AA, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS 2001;15:140-1 (Pubitemid 32055797)
87. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl] adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004;48:1469-87 (Pubitemid 38544348)
88. Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk ofrenal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010;24:525-34
89. Angel-Moreno-Maroto A, Suarez-Castellano L, Hernandez-Cabrera M, et al. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J Infect 2006;52:e39-40 (Pubitemid 43137401)
90. Barbour TD, Furlong TJ, Finlayson RJ. Efavirenz-associated podocyte damage. AIDS 2007;21:257-8
91. Wirth GJ, Teuscher J, Graf JD, et al. Efavirenz-induced urolithiasis. Urol Res 2006;34:288-9 (Pubitemid 44127148)
92. Curry E, Thomas M, Yehia M. Renal impairment and hypersensitivity reaction due to efavirenz. Nephrology (Carlton) 2008;13:541
93. Knudtson E, Para M, Boswell H, et al. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol 2003;101:1094-7 (Pubitemid 36566389)
94. Feicke A, Rentsch KM, Oertle D, et al. Same patient, new stone composition: amprenavir urinary stone. Antivir Ther 2008;13:733-34
95. Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 1999;340:392-3 (Pubitemid 29090811)
96. Iba-Ba J, Yombi JC, Danse E, et al. Bilateral papillary necrosis during indinavir treatment. Presse Med 2008;37:967-9
97. van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatrics 2002;110:e19
98. Stricker RB, Man KM, Bouvier DB, et al. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIVinfection. Lancet 1997;349:1745-6 (Pubitemid 27252680)
99. Doco-Lecompte T, Garrec A, Thomas L, et al. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS 2004;18:705-6 (Pubitemid 38393477)
100. Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol 2002;167:1384-5 (Pubitemid 34132100)
101. Green ST, McKendrick MW, Schmid ML, et al. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS 1998;9:555 (Pubitemid 28423490)
102. Zhang X, Lalezari JP, Badley AD, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004;75:558-68 (Pubitemid 38746606)
103. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41
104. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12 (Pubitemid 47047471)
105. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
106. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5 (Pubitemid 44306480)
107. Parkhie SM, Fine DM, Lucas GM, et al. Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol 2010
108. De Vriese AS, Robbrecht DL, Vanholder RC, et al. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis 1998;31:108-15 (Pubitemid 28116691)
109. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002;6:622-7 (Pubitemid 36898188)
110. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-07 (Pubitemid 30022731)
111. Becker BN, Fall P, Hall C, et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis 1993;22:611-15 (Pubitemid 23308976)
112. Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988;84:1067-71
113. Ha NB, Garcia RT, Trinh HN, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-34
114. Ljungman P, Deliliers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97:388-92 (Pubitemid 32060322)
115. Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998;32:392-400 (Pubitemid 28411211)
116. Navarro JF, Quereda C, Gallego N, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996;27:431-4 (Pubitemid 26075855)
117. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991;324:1005-11